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tients and controls and were related to the vitamin D status. The Th17 cell population was expanded in about
40% of the MS patients. In MS patients in remission, but not during relapse, a positive association was found
between Th17 cell and CD39+ Treg percentages (r=0.468, p=0.007). Since CD39+ Tregs have been shown
to have Th17 suppressive capacities, we propose that a dysregulated Th17/CD39+ Treg balance might con-
tribute to disease exacerbation. A clear role for vitamin D in this regulation could not be established.
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Multiple sclerosis (MS) is an inﬂammatory disease of the central
nervous system (CNS). Both genetic and environmental factors are in-
volved in the pathogenesis of MS (Compston and Coles, 2008). A well
established environmental risk factor is a poor vitamin D status
(Ascherio et al., 2010). It is speculated that vitamin D is important in
the maintenance of peripheral T cell homeostasis and thus self-
tolerance. In particular, in the early inﬂammatory phase of relapsing-
remitting (RR) MS, T cell homeostasis is disturbed (Venken et al.,
2006; Compston and Coles, 2008). Although regulatory T cells (Treg)
are normal in number, they are functionally deﬁcit, eventually enabling
pathogenic T helper (Th) 17 and Th1 effector functions (Viglietta et al.,
2004; Haas et al., 2005; Venken et al., 2006). In vitro studies showed
that vitamin D can induce regulatory T cells, shifts the Th1/Th2 balance
in favor of Th2 cells, and inhibits differentiation into Th17 cells (as
reviewed by Peelen et al., 2011). In a cross-sectional study, we demon-
strated that the vitamin D status of RRMS patients correlated negatively
with the peripheral Th1/Th2 ratio,while a positive correlationwith Treg
function, but not number, was observed (Smolders et al., 2009). Highand Neuroscience, Maastricht
5.302, PO Box 616, 6200 MD
.nl (E. Peelen).
vier OA license.dose vitamin D supplementation in healthy controls has been shown
to induce a marginal increase in Treg number (Prietl et al., 2010). How-
ever, we could not reproduce this ﬁnding in RRMS patients, but we
found a reduced Th1/Th2 ratio and an increased proportion of IL-10+
CD4+ T cells (Smolders et al., 2010).
Recently, it became apparent that Tregs can be divided in two sub-
sets based on the expression of CD39, a membrane bound ectonucleoti-
dase (Borsellino et al., 2007). CD39+ Tregs, but not CD39− Tregs, have
the potential to suppress the pathogenic IL-17 producing CD4+ T cells
(Fletcher et al., 2009). CD39− Tregs, on the other hand, are able to pro-
duce IL-17 themselves (Fletcher et al., 2009). Interestingly, CD39+ Treg
numbers have been reported to be reduced in RRMS patients as com-
pared to healthy controls (Borsellino et al., 2007; Fletcher et al., 2009).
Furthermore, CD39+ Tregs of RRMS patients were less capable to sup-
press IL-17 producing CD4+ T cells, while CD39− Treg function did
not differ between patients and controls (Fletcher et al., 2009).
In the current study, we hypothesized that vitamin D affects the
peripheral T cell homeostasis by interfering with the relative pres-
ence of CD39+ Tregs and subsequently Th17 cells. We ﬁrst examined
the numbers of IL-17+ CD4+ T cells and CD39+ Tregs in RRMS pa-
tients during quiescent and active disease and in healthy controls.
Second, we searched in the same cohorts for an association between
these T cell subsets. Finally, we investigated whether IL-17 producing
CD4+ T cells and CD39+ Tregs were associated with the vitamin D
status in RRMS patients and healthy controls.
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2.1. Patients and blood samples
Thirty-two RRMS patients in remission, 22 RRMS patients during a
relapse, and 30 healthy controls, matched for age and gender with the
RRMS patients in remission, were enrolled in this study. All MS pa-
tients were retrieved from the Academic MS Center Limburg at
Orbis Medical Center (Sittard, the Netherlands) and had a relapsing-
remitting (RRMS) disease course, as deﬁned by the revised McDonald
criteria (Polman et al., 2005). A relapse was deﬁned as occurrence of
new symptoms which lasted at least 24 h and which required treat-
ment with intravenous methylprednisolone. Blood sampling in the
relapse patients took place before methylprednisolone infusion.
Seven patients from the relapse cohort were analyzed again after re-
covery from the relapse. All blood samples for T cell phenotyping and
vitamin D analyses were retrieved simultaneously. Written informed
consent was obtained from each study subject and this study was ap-
proved by the regional ethical committee ‘Atrium-Orbis-Zuyd’.
Population characteristics are depicted in Table 1. Disease dura-
tion was b6 years and patients had to be in remission for >6 weeks
before inclusion in the MS remission cohort. For inclusion in this
study, MS patients were allowed to use Beta Interferon (IFN-β) 1a
or 1b, but no other disease modulating drugs. Eighteen patients
(56.3%) of the MS remission and 10 patients (45.5%) of the MS relapse
cohort were on IFN-β therapy.
2.2. Serum 25(OH)D assessment
Immediately after sampling, the serum was stored at −20 °C till
analysis. Serum 25(OH)D levels (vitamin D status) were determined
with a radioimmunoassay kit (Immunodiagnostic Systems, Boldon,
UK).
2.3. T cell phenotyping
Peripheral blood mononuclear cells (PBMC) were isolated using
Ficoll density gradient centrifugation (Histopaque; Sigma Aldrich,
Zwijndrecht, The Netherlands). Surface staining was performed with
anti-CD3-Horizon V450, anti-CD4-APC-H7, anti-CD25-PE-Cy7 (all BD
Biosciences, Breda, Netherlands), anti-CD127-FITC and anti-CD39-
APC (all eBiosciences, Halle-Zoersel, Belgie). Tregs were deﬁned as
CD4+ CD25high CD127low cells (Liu et al., 2006; Seddiki et al., 2006).
We have previously shown that these Tregs have a suppressive capac-
ity (Smolders et al., 2009; Smolders et al., 2010). The CD4+ T cellTable 1
Population characteristics.
Healthy controls Remission Relapse
Median (IQR)/
N (%)
Median (IQR)/
N (%)
Median (IQR)/
N (%)
Gender
Female N=22 (73.3%) N=25 (78.1%) N=16 (72.7%)
Male N=8 (26.7%) N=7 (21.9%) N=6 (27.3%)
Age (years) 41 (31–47) 43 (30–48) 32 (28–43)
Disease duration (years) – 3.12 (1.63–4.33) 2.55 (0.56–3.79)
Time since last relapse
(years)
– 1.12 (0.45–2.92) 0.96 (0.46–2.01)
Number of relapses last
year
– 0 (0–1) 1 (0–1)
EDSS score – 1.5 (1.0–3.0) 2.25 (1.0–2.5)
Treatment
None – N=14 (43.8%) N=12 (54.5%)
IFN-β – N=18 (56.3%) N=10 (45.5%)
Vitamin D status (nmol/L) 87.5 (68–95) 79.5 (63–107) 64 (49–89)
EDSS=Expanded Disability Status Scale.cytokine proﬁle was assessed by intracellular cytokine expression of
CD3+ CD8− lymphocytes, i.e. CD4+ T cells, as described before
(Smolders et al., 2010). In short, PBMC were stimulated for 5 h with
1 μg/mL calcium ionomycine (Sigma Aldrich) and 50 ng/mL PMA
(Sigma Aldrich) and cytokine secretion was blocked with monensin
(BD Biosciences) for 5 h. Cells were stained extracellularly with
anti-CD3-horizon V450 and anti-CD8-APC-H7 (BD Biosciences) and
intracellularly with anti-IL-17A-PerCP-Cy5.5 and anti-CD69-PE-Cy7
(all Biolegend, Uithoorn, Netherlands). CD69 expression was included
to conﬁrm the activation status of the cells. All samples were acquired
on a FACS Canto II ﬂowcytometer (BD Biosciences) and data were an-
alyzed with FACS Diva software.
2.4. Statistics
Statistical analysis was performed with Statistical Package for So-
cial Sciences version 15.0 software (SPSS inc., Chicago IL, USA). Re-
sults are presented as median with corresponding interquartile
range (IQR) for continues variables. Differences between groups
were tested using the Mann–Whitney U test. Correlations were tested
with the Spearman correlation. To compare percentages of cell sub-
sets in RRMS patients during relapse and subsequent remission, the
Wilcoxon Signed Ranks test was performed. A cut-off point based
on IL-17+ CD4+ T cell percentages from MS patients in remission
compared to healthy subjects was calculated using the receiver oper-
ating characteristic (ROC) curve analyses. Differences between the
groups in IL-17+ CD4+ T cell percentages above and underneath
the cut-off were tested using the Chi-squared test. A p-value b0.05
was considered statistically signiﬁcant.
3. Results
3.1. CD39+ Tregs in RRMS patients in remission and during a relapse
The percentages of total Tregs, deﬁned as the relative amount of
CD25high CD127low T cells within the CD4+ T cell population, did
not differ signiﬁcantly between HC (4.8%, 4.0–5.4), MS patients in re-
mission (4.9%, 3.9–6.7) and MS patients during relapse (5.3%, 4.1–
6.3). Since CD39 expression discriminates between two distinct Treg
subsets, we next analyzed the fraction CD39+ cells within the Treg
population as well as the relative amount of CD39 expressing Tregs
within the CD4+ T cell population (Fig. 1). The latter may be more rel-
evant as outcome measure since, at least in vitro, the ratio between
Tregs and responder T cells is used to determine Treg function. The
fraction CD39+ Tregs (% of CD4+ T cells) was not different for HC
(1.8%, 1.2–2.6), MS patients in remission (2.1%, 1.3–2.9) and MS pa-
tients during relapse (1.7%, 0.6–2.8) (Fig. 1B). Similar results were
obtained when the CD39+ cells were analyzed within the Treg popu-
lation (Fig. 1C). Interestingly, the latter analysis revealed a dichotomy
in the relapse cohort. Nine patients had a percentage of CD39+ cells
within the Treg population close to the median value of the HC and
the MS patients in remission, while 13 patients had very low percent-
ages of CD39+ cells within the Treg population (Fig. 1C). The dichot-
omy in the distribution of CD39+ cells within the Treg population
could not be explained by differences in the severity of the relapse
(objective/subjective or sensible/motor function or presence of optic
neuritis). Next, we analyzed whether the percentage of CD39+ cells
within the Treg population normalized when the MS patients were
again in remission. Seven patients were re-analyzed while in remis-
sion, 3 to 9 months after the relapse. The results revealed that the
percentage of CD39+ cells within the Treg population was stable in
time (Fig. 1D). Therefore, the dichotomy might be explained by previ-
ous disease activity parameters. However, there was no association
with disease duration, EDSS score before relapse, time since last re-
lapse, relapse rate, or number of relapses since onset of the disease,
neither with use of medication, gender, or age (data not shown).
Fig. 1. CD39+ Tregs in healthy controls and MS patients in remission and during relapse. A) PBMC were stained with antibodies to CD3, CD4, CD25, CD127 and CD39. First, CD3+
CD4+ T cells were gated within the lymphocyte gate. Subsequently, CD25high CD127low cells (Tregs) were gated and analyzed for CD39 expression. B) The percentage of CD39+
CD25high CD127low cells (CD39+ Tregs) within the total CD4+ T cell population and C) the percentage of CD39+ cells within the CD4+ CD25high CD127low regulatory T cell
(Treg) population in healthy controls (n=30), MS patients in remission (n=32) and MS patients during relapse (n=22). Statistic analysis was performed with the Mann–Whit-
ney U test. D) The percentage of CD39+ cells within the Treg population in MS patients (n=7) was determined during a relapse (MS Relapse) and subsequently during stable dis-
ease (MS Remission). The Wilcoxon Signed Ranks test was performed. A p-value b0.05 is considered statistically signiﬁcant.
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CD39+ Tregs have been shown to suppress IL-17 secretion and to
reduce the fraction of IL-17 producing pro-inﬂammatory CD4+ T cells
(Fletcher et al., 2009). Hence, we assessed the percentages of IL-17+
cells within the CD4+ T cell population and related these to the frac-
tion CD39+ Tregs (% of CD4+ T cells). The median percentage of IL-
17+ CD4+ T cells was not signiﬁcantly different between the HC
(0.8%, 0.6–0.9), the MS remission (0.8%, 0.4–1.3) and the MS relapse
cohort (0.9%, 0.6–1.4) (Fig. 2A). However, using a cut-off value of
1.05% (as determined by ROC curve analysis), 37.5% of the MS pa-
tients in remission and 45.5% of the MS patients during a relapse ver-
sus 3.3% of the healthy controls had an elevated percentage of IL-17+
cells within the CD4+ T cell population (pb0.01; Fig. 2A). In the MS
remission cohort, the IL-17+ CD4+ T cell fraction correlated positive-
ly with the fraction of CD39+ Tregs within the CD4+ T cell population
(r=0.468, p=0.007; Fig. 2B). No such association was observed in
the MS relapse (Fig. 2C) or the HC cohort (Fig. 2D).
Finally, we calculated the relative presence of CD39+ Tregs to IL-
17+ CD4+ T cells (ratio of CD39+ Tregs/IL-17+ CD4+ T cells,
Fig. 2E). This ratio did not differ between HC and MS patients in re-
mission. However, we observed a tendency towards a lower CD39+
Tregs/IL-17+ CD4+ T cells ratio in MS patients experiencing a relapse
(p=0.067). Interestingly, when the MS relapse cohort was split upbased on the dichotomy described in Fig. 1C, a signiﬁcantly
(p=0.001) lower CD39+ Treg/IL-17+ CD4+ T cell ratio was observed
in the subgroup with low relative amounts of CD39+ cells within the
Treg compartment (data not shown).
3.3. Correlation of serum 25(OH)D levels with proportions of Th17 cells
and CD39+ Tregs
To investigate whether the percentage of CD39+ Tregs is associat-
ed with the vitamin D status, serum 25(OH)D levels were determined
in the HC, the MS remission and the MS relapse cohort. The median
serum 25(OH)D level (Table 1) was signiﬁcantly lower in the MS re-
lapse cohort (64.0 nmol/L, 49–89) compared to the HC cohort
(87.5 nmol/L, 68–95) (p=0.022) and RRMS patients in remission
(79.5 nmol/L, 63–107) (p=0.036). Serum 25(OH)D levels did not
differ signiﬁcantly between healthy controls and RRMS patients in
remission.
Serum 25(OH)D levels did not correlate with the percentage of IL-
17+ CD4+ T cells in either of the three study cohorts (Fig. 3A–C).
However, in the MS remission cohort, the patients with an elevated
percentage of Th17 cells (>1.05%) tended to have lower vitamin D
levels as compared to those without an expanded Th17 population
(p=0.059). Surprisingly, a negative correlation of serum 25(OH)D
levels with the CD39+ Treg fraction was observed in the MS
Fig. 2. Correlation of percentage of IL-17+ cells within the CD4+ T cells with CD39+ Treg. A) The percentage of IL-17+ cells within the CD4+ T cell population in the three study
cohorts. B, C and D) The percentage of IL-17+ CD4+ T cells is plotted against the percentage of CD39+ CD25high CD127low cells (CD39+ Tregs) within the total CD4+ T cell popu-
lation in the MS remission (B), the MS relapse (C) and the healthy control cohort (D). E) The ratio of CD39+ Tregs and IL-17+ CD4+ T cells in the three study cohorts. All plots are
based on 30 healthy controls, 32 MS patients in remission and 22 MS patients during relapse. The dotted line in A reﬂects the cut-off point as determined with the receiver operator
characteristics curve analysis comparing healthy controls with MS patients in remission. Differences between study cohorts were tested with the Mann–Whitney U test (A and E).
The Spearman correlation coefﬁcients and the p-values are depicted in the graphs (B–D). A p-valueb0.05 is considered statistically signiﬁcant.
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tion was found in the MS relapse (Fig. 3E) or the healthy control co-
hort (Fig. 3F).
4. Discussion
The present cross-sectional study revealed three interesting ﬁnd-
ings. First, although CD39+ Treg percentages were similar in MS pa-
tients in remission or during a relapse and healthy controls, CD39+
Treg percentages correlated positively with the fraction of IL-17+
CD4+ T cells within the MS remission cohort, but not in the MS re-
lapse cohort or HC. Second, CD39+ cell percentages within the Treg
population revealed a dichotomous distribution in the MS relapse co-
hort which was stable over time. Third, vitamin D levels are relativelylow in MS patients with increased percentages of IL-17+ CD4+ T cells
while, surprisingly, vitamin D levels inversely correlate with the frac-
tion of CD39+ Tregs. These ﬁndings on vitamin D only hold for MS pa-
tients in remission.
CD39+ Tregs appear to be a subset of the CD25high CD127low Tregs
(Borsellino et al., 2007). Fletcher et al. demonstrated that this Treg
subset is able to suppress Th17 cells (Fletcher et al., 2009), unlike
the CD39− Tregs (Fletcher et al., 2009; Dwyer et al., 2010). Recently,
Ye et al. (2011a, 2011b) showed that CD39+ Tregs are also able to
suppress Th17 cells in patients with tuberculosis and in patients
with lung cancer. Increased CD39+ Treg percentages might interfere
with the development of an appropriate immune reaction as was
demonstrated for infectious diseases, including tuberculosis and
HIV, and cancers, such as follicular lymphomas (Chiacchio et al.,
Fig. 3. Correlation of IL-17+ CD4+ T cells and CD39+ Tregs with vitamin D status. A, B and C) Percentages of IL-17+ CD4+ T cells are plotted against serum 25(OH)D levels in MS
patients in remission (A), MS patients during relapse (B) and healthy controls (C). D, E and F) Percentages of CD39+ CD25high CD127low cells (CD39+ Tregs) within the total CD4+ T
cell population are plotted against serum 25(OH)D levels in MS patients in remission (D), MS patients during relapse (E) and healthy controls (F). All plots are based on 32 MS
patients in remission, 22 MS patients during relapse and 30 healthy controls. The Spearman correlation coefﬁcients and the corresponding p-values are depicted in the graphs.
A p-valueb0.05 is considered statistically signiﬁcant.
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other hand, decreased CD39+ Treg percentages might allow or en-
hance autoimmune reactions. In this study, we demonstrated that
CD39+ Treg percentages are comparable between HC and MS pa-
tients both in remission and during a relapse. In contrast, three previ-
ous studies reported reduced CD39+ Treg percentages in RRMS
patients during remission (Borsellino et al., 2007; Fletcher et al.,
2009; Libera et al., 2011), while CD39+ Treg percentages during a re-
lapse were in line with our data (Libera et al., 2011). The discrepan-
cies between our data and the former studies with regard to CD39+
Treg percentages in RRMS patients during remission might ﬁrst be
explained by Treg deﬁnition. Two studies used a less stringent Treg
deﬁnition, CD4+ CD25high CD39+ percentages (Borsellino et al.,
2007; Libera et al., 2011), compared to our paper. Moreover, Libera
et al. deﬁned their CD39+ Tregs as percentages of total PBMC popula-
tion. In another paper, Tregs were deﬁned as CD4+ CD25high
CD127low FoxP3+ T cell percentages (Fletcher et al., 2009). Secondly,
population characteristics of the RRMS study cohorts might differ im-
portantly between the different studies. In the studies of Borsellino et
al. (2007) and Fletcher et al. (2009), MS patients did not use any im-
mune modulatory medication at the moment of inclusion, while the
majority of the MS patients in our study used IFN-β. Furthermore,
the disease duration in one study (Libera et al., 2011) is longer com-
pared to the disease duration of our MS patients. In the other two
studies, the disease duration was not mentioned (Borsellino et al.,
2007; Fletcher et al., 2009). Finally, Fletcher et al. (2009) compared
the MS cohort to a healthy control cohort, but information about pos-
sible matching with the disease cohort was not provided.
In the MS relapse cohort, we observed a dichotomy in CD39+ Treg
percentages. The low CD39+ Treg percentages in a subgroup of the
MS patients during a relapse could imply a lower capacity to suppress
IL-17 secreting CD4+ T cells, a T cell population that is believed to bepathogenic in MS. Therefore, a relation between CD39+ Treg percent-
ages and disease severity or duration or relapse rate was investigated.
However, CD39+ Treg percentages were not related to any patient
characteristic. Another possibility is that CD39 is downregulated,
like CD28 on CD4+ T cells (Bryl et al., 2001), upon excessive activa-
tion of the Tregs by the repeating occurrence of relapses. Hence,
CD39+ Treg percentages might be associated with the total number
of relapses. However, we did not ﬁnd such an association. CD39+
Treg percentages were also assessed after recovery from the relapse.
We showed that CD39+ Treg percentages are stable in time, since
low percentages of CD39+ Tregs are not restored in remission.
These data indicate that ﬂuctuations in CD39+ Treg percentages do
not account for the observed dichotomy. Altogether, we have not
been able to explain the dichotomy in CD39+ Treg percentages in
the relapse cohort and can therefore not exclude the possibility that
this ﬁnding was based on coincidence.
Th17 cells are considered to be important in MS pathogenesis
(Kebir et al., 2007; Steinman, 2007). In contrast to Durelli et al.
(2009), we observed no difference in median Th17 cell frequencies
between MS patients and healthy controls. However, we demonstrat-
ed that about 40% of the MS patients during a relapse as well as in re-
mission had an increased frequency of Th17 cells. These results imply
a disturbance in the regulation of Th17 cells in these MS patients.
Here, we investigated the relation between circulating CD39+ Tregs
and Th17 cells. In the MS remission cohort, but not in the MS relapse
cohort, we observed that higher IL-17+ CD4+ T cell percentages were
accompanied by higher CD39+ Treg percentages. Since CD39+ Tregs
have been shown to have the ability to suppress Th17 cells, the ob-
served positive correlation in the MS remission cohort may reﬂect a
mechanism to compensate for the expanded Th17 subset. Interesting-
ly, in MS patients during a relapse, expansion of the Th17 cell popula-
tion is not counterbalanced by an expansion in CD39+ Treg
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might contribute to the development of an exacerbation of disease.
Recently, Wilson et al. (2011), showed that an adenosine analog, in
combination with IL-6, is able to induce Th17 cells. Adenosine is a
molecule that is produced upon conversion of adenosine triphosphate
(ATP) by CD39 in combination with CD73 (Bours et al., 2006). A frac-
tion of CD39+ Tregs has been shown to co-express CD73 (Alam et al.,
2009; Mandapathil et al., 2010). The induction of Th17 cells by CD39+
Tregs could therefore be an alternative explanation for the observed
positive correlation between percentages of Th17 cells and CD39+
Tregs.
Our data showed no correlation between serum 25(OH)D levels
and Th17 cell percentages. However, in the MS remission cohort,
the group with elevated Th17 cell percentages (>1.05%) had a trend
towards lower vitamin D levels. This is in concordance with in vitro
studies that show that vitamin D is able to decrease the percentages
of Th17 cells (as reviewed by Peelen et al., 2011). Furthermore, an as-
sociation between CD39+ Treg frequencies and the vitamin D status
was investigated. Surprisingly, an unexpected negative correlation
between CD39+ Treg percentages and serum 25(OH)D levels was ob-
served in the MS remission cohort exclusively. We speculate that this
association is mediated through Th17 cell percentages. Low vitamin D
levels might enable Th17 expansion and this may then cause com-
pensatory CD39+ Treg expansion.
The strength of our study is that we are, to our knowledge, the ﬁrst
to connect the vitamin D status with CD39+ Treg percentages in a
cross sectional study. In addition, we were able to compare CD39+
Treg percentages and associations with other parameters both during
quiescent and active RRMS. However, this study has some short com-
ings. The cross sectional study design does not allow to draw conclu-
sions with respect to causality. Furthermore, we assessed CD39+
Tregs in the peripheral circulation, but it would be even more inter-
esting to assess these T cell subsets in the cerebral spinal ﬂuid and
in brain tissue. Finally, the lack of clear associations between CD39+
Treg percentages and vitamin D status does not exclude the possibil-
ity that vitamin D affects CD39+ Treg function instead of CD39+ Treg
numbers. Also in case of conventional Tregs, a correlation was only
observed with vitamin D status when analyzing the function of
these cells (Smolders et al., 2009). Therefore, it would be interesting
to study CD39+ Treg function in future studies.
In conclusion, the control of Th17 cells seems to be disturbed in
MS patients. MS patients in remission seem able to cope with this dis-
turbance by a counterbalanced expansion of CD39+ Tregs. Although
vitamin D is important for maintaining immune homeostasis, as sup-
ported by our ﬁnding that with expansion of Th17 cells have relative-
ly low levels of vitamin D, we could not demonstrate a
comprehensible relation between vitamin D status and CD39+ Treg
percentages. Upcoming vitamin D supplementation studies will en-
able to study the effect of vitamin D on CD39+ Tregs and IL-17+
CD4+ T cells in a prospective study design.
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